We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Joint Committee on Drugs Use

Decriminalisation, Depenalisation, Diversion and Legalisation of Drugs: Discussion (Resumed)

Contributions 118–242 of 242. This sitting's record is too long for one page, so it is split into 2 parts.

Dr. Diarmuid Quinlan

They can progress in parallel. Decriminalisation and a comprehensive, adequately resourced, health-led approach can absolutely happily proceed in parallel.

Comment on this
Mr. Tom Murray

They have to progress in parallel and where, as our GP colleagues have outlined, criminalisation is a barrier to access to healthcare for the patient. That is fundamental. We are all patient-centred professional practitioners. That is what we do. Therefore, where you see criminalisation is a barrier to access to healthcare for a patient, that is not something we can necessarily stand over and say it is a good policy.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

I thank Mr. Murray.

To move on from that, I was really delighted to see the sentence "human-rights based" in there. What does that look like in real terms? We had a conversation regarding alternatives to methadone as a treatment being readily available but some communication to me indicates there is no choice on that. It is health-rights-based but then there is no choice in that about whether you are going to get methadone or you can go in and have some agency or autonomy to say you would rather try Suboxone or one of the other forms. From that perspective, when somebody goes in and is being put on an OST treatment, can they choose in that moment which one they try or is methadone cheaper or more readily available? Is there a price thing or anything in that?

Comment on this
Dr. Bernard Kenny

As medical practitioners, price would not come into it certainly. That is not something we ask. We would not consider that. We would consider the most appropriate treatment for that person. In certain circumstances, depending on the substances involved, different opioid agonist therapies, which is what we call methadone and Suboxone, may be more appropriate. We would always make our decisions with the patients involved. The vast majority of practitioners have moved on from a paternalistic model of care where we impose our judgments. It is all around shared decision-making now. In most practices, you would not prescribe a treatment that someone was not comfortable with, or certainly would never force somebody onto a treatment. Occasionally methadone may be the more appropriate treatment and you explain the rationale for that, depending on the risks from other substances they may be taking, interactions with medications, or certain other chronic diseases that co-exist alongside the addiction. Certain people may have advanced liver disease and other things as well and that may affect their treatment option. It should be informed shared decision-making. Certainly, the ICGP would always support that approach.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

When GPs carry out the training, they are granted the list and are able to take on patients for methadone or other options. There seems to be something happening in some counties outside Dublin where people need treatment. The doctors are saying they have done the training and have signed up but are not receiving any patients. However, other doctors are receiving many patients. Who decides where patients go? Will Dr. Kenny explain the process to me? When a GP says they want to go on the list and be a doctor who provides that care, what is happening in the decision-making? A patient may be saying they want to be with the doctor who is closest to them but there seems to be someone else making the decision that they are going to go to another doctor. Some doctors are saying they have been given no patients while other doctors in the next town over has loads of patients but they are also from closer to our community.

Comment on this
Dr. Bernard Kenny

The process is that we offer the training to train GPs up to have advanced specialty in addiction medicine. We provide that training through ICGP. Once the training is completed and they have met the standards of that training, the HSE will offer a contract or the GPs can apply for a contract through their local HSE co-ordinator. Depending on the level of training, they are then in a position to inherit existing patients who are already prescribed an opioid agonist therapy, or if they complete level 2 training they can complete a full assessment and implement their own management from scratch in the community where they are. We recognise that is the preferential place for people to receive their therapy.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Is it the HSE co-ordinators who are then deciding on where patients go or is it higher up in terms of the central list?

Comment on this
Dr. Bernard Kenny

I imagine patient preference has a role, as does the HSE co-ordinator. Dr. Crowley may be able to answer more on that.

Comment on this
Dr. Des Crowley

Yes, it is the GP co-ordinator and the pharmacy liaison person.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Okay. They are making the decisions. As I said, there are GPs in one or two counties specifically who are saying they are trained and there are patients but they are not being sent to them. They are a bit confused by that. Perhaps that can be dealt with separately. I can ask them to make contact with the appropriate people.

I have two final questions but I will put them together. One is in relation to benzodiazepine detox within the community. I think I did benzo training with Dr. Crowley when I was probably 20. This is how long it has been. It was nearly 20 years ago. I cannot believe I am at this stage in my life where I am saying "20 years ago I...". That is how long ago - and even before that - the conversation around benzos has been going on but we do not seem to be any further regarding having a national plan or framework for benzo detox within the communities. I understand the concerns and GPs being concerned about people topping up on the streets and all of that. Are we any closer to having any sort of strategy around people having access to benzo detox within their communities? That is the first question.

The second question is regarding the likes of tramadol and oxycodone and people being outside of that ordinary framework of what people maybe consider as someone being in addiction. I refer to men and women who are going out to work but a lot of them have developed serious addictions to the likes of tramadol or Ixprim, which is the dissolving one. The only option that has been given to one or two people I have spoken to has been that they go on a methadone programme. Obviously, this would be completely outside of their realm of daily life. They are not in drug-using communities and it is not that their peers are. It is a difference culturally. Are the witnesses seeing much of that? Are many people ending up on methadone treatment programmes from the likes of tramadol addiction? I am still at a loss to understand where it is all happening. From a point of information, I just do not understand.

Comment on this
Dr. Des Crowley

I will take the question on codeine dependence. Certainly, codeine dependence is equivalent to opioid dependence but it is a different drug. The Leas-Chathaoirleach is right that it is a different cohort and they have different needs. In the areas in which I work in my own practice, the first line of treatment would be to provide people with buprenorphine. We are progressing another OST option now which is depot buprenorphine. This is a monthly injection which has revolutionised a huge number of people's lives, particularly in the patient cohort we are talking about, because they only need to go once a month to get their depot. That is the type of service for which primary care is ideally placed because that is where you come into further discrimination and stigma. They need to go to their general practitioner. They need to have a GP who has that specialist skill to assess and then to provide the treatment. That is where we would be advocating for in ICGP.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Does there need to be some sort of public information for people to know they can go to talk to their doctor about the tramadol addiction?

Comment on this
Dr. Des Crowley

It is an enormous situation and we have tipped the iceberg on it. Part of it is the historical way our services have been set up. They were methadone-based and related to heroin use because that was the predominant opioid that was used but now codeine is definitely a sleeper and there is a huge issue there.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Okay. I thank Dr. Crowley. The other question was on whether there were conversations regarding the benzo detoxes.

Comment on this
Dr. Denis O'Driscoll

From my experience when I was in the addiction services, we certainly offered benzodiazepine detoxes within the confines of our addiction treatment services. They were always patient-driven because that is the only way it will work. It is pointless me dropping somebody automatically. As regards detoxes within the community, there was a project on the northside of the city which was very much based around community GPs and the patients themselves with local pharmacies to look at how benzo detox could and should work.

The challenge around benzodiazepine detox is people always ask how long. My opinion on a detox is it is as long as a person needs it for, but the whole rationale for it is that within our addiction services, we could change things more regularly. That means I could ring Dr. Crowley up and say the Leas-Chathaoirleach is not ready to drop down a dose and we need to keep her on this particular dose, so we would keep her at that. Out in the community there is a whole scope, including needing prescriptions, interventions and regular interventions. It is just a more difficult situation out in the community. I concur with the Leas-Chathaoirleach. In 2000, I think, the benzodiazepine subcommittee was set up, so it has indeed been that long. We have talked about it since that.

Comment on this
Dr. Des Crowley

Many more GPs would get involved in benzo detoxification if the support structures were in place. Most GPs fear being left with a patient on a benzodiazepine prescription, finding it hard to reduce or come off it and then we get into the issue of overprescribing and being identified, whereas these patients are benzodiazepine-dependent, so the prescribing of benzodiazepines to dependent people is actually good practice.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

It is good practice. That collaboration piece is important to ensure a doctor is very well linked in with the local community services, so it is a more holistic approach across the board within the community. I will go to Dr. Quinlan and move on.

Comment on this
Dr. Diarmuid Quinlan

I will be very brief. I absolutely get what my colleagues are saying about the detox. Equally, there is a much bigger piece about not initiating people on benzodiazepines in the community. That is a challenge in itself and one the Medical Council is addressing in conjunction with all the professional bodies. Again, we need a whole-system approach. It is not initiating people in benzos as much as possible and keeping the dose as low as possible for the shortest duration. We are very happy to work with our colleagues to try to address this problem.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

It is not to fully say that is where benzo addiction comes from. Obviously, prescribing is a big part, but a lot of benzo addiction is starting anyway within the illegal market without it ever having been prescribed, so there are definitely two cohorts or transitions happening there. Senator Seery Kearney is next.

Comment on this

I always love the Leas-Chathaoirleach's questions. I thank the witnesses, as this has been an incredibly respectful conversation, as well as unbelievably illuminating. I always hated the term "drug addict". People are not drug addicts, but mothers, sons and fathers. They are people who have dreams, hopes and everything for their lives and I am very much influenced by Gabor Maté's writings on his encounters with his patients and how honest he is about his prejudices and all the complexity of patients as they present. We are really respectful here and I hear that from both organisations in a way I just love.

I have three areas of questions. I thank Dr. Quinlan for talking about the Medical Council and prescriptions. I worked as a counselling psychologist in Ballyfermot for a number of years. I felt there was an instant prescribing. I would have someone coming through counselling and all of a sudden they had gone to a doctor who was prescribing. I often wondered whether there was an issue of fear of litigation with doctors, namely, that if somebody has a particular presentation there is a fear of not prescribing or something along those lines. Are there impediments there we should be lifting? If you are involved in the counselling process it prolongs it. I, unusually, would be of the view that my job was to get a person to a place where they had the skills to be able to live their life rather than forever coming to me. I feel prescribing is too quick, but I also respect very much what Dr. Crowley was saying around benzos, the detox and all that and that there is really good practice on prescribing. I would like to comment on that more.

I love that Mr. Murray took a stand, despite the political considerations, to ensure there was a needle exchange and that people had somewhere to come to. There is a responsibility to tackle the denial among the public and as a nation and to deal with the stigma. Every community, no matter where they are, has people who have addiction issues, especially in the area of drugs. It may be masked in more upwardly mobile communities than it is in socially deprived communities and my home constituency of Dublin South-Central particularly, but it is there and so we should have the response there. I would love for us to move so we have a response when it comes to naloxone that is almost like what we have with EpiPens.

As the witnesses speak and as I hear the amazing insights and the responses, I think of my role as chair of a drugs task force. I have had the privilege of being involved in the Dublin 12 local drugs and alcohol task force since 2019. On that, we have the Garda, the HSE, probation services and practitioners, but we have no pharmacists and no doctors. I wonder whether that could be better informed structurally because at every meeting we deal with trends and what is emerging in the community. Maybe we would have better community responses if we looked structurally at that level of greater response as part of the community change and ramping up the health response and moving to that. I am interested in hearing the witnesses' comments on that.

Comment on this
Dr. Diarmuid Quinlan

I will take the first one. I agree with what the Senator says about mental health. We have broadened to mental health in primary care. I and my colleagues are resourced to provide care for people with chronic diseases such as asthma, diabetes, heart failure and so on. There is currently no resourcing at all in primary care for mental health illness. Depression, anxiety and psychotic illness are not resourced in general practice. When it is not resourced, inevitably it is competing for limited availability of GP time and space with areas that are resourced. We have the capacity to provide enhanced mental health service in primary care, but we need resourcing. We have heard a lot about the contraceptive piece in the last while, but there is no resourcing for mental health in primary care. That is a fundamental-----

Comment on this

We need to name that and call it out.

Comment on this
Dr. Diarmuid Quinlan

-----building block to enable patients to get the care they need across the full spectrum of mental health.

Comment on this
Dr. Des Crowley

Going back to our original statement, we talk about increased funding for the talking therapies and there are a lot of addictions that is the only evidence base for. I refer to cognitive behavioural therapy. That is the basis of how we make people better and it is really poorly resourced and very difficult to access.

Comment on this

I am a Belfast boy and I want to raise something in relation to the submission from the Irish College of General Practitioners. In Northern Ireland we had 218 deaths in 2020 and 213 in 2021. The ONS would say that is 11.5 per 100,000. Scaled up that is 115 per million, which is higher than the rate here in Ireland. The challenge of that is when we look at the European statistics we take the UK as a unitary state, but there are subtle differences in reporting across the four nations. We have a particular circumstance in the North, which is post-conflict endemic poverty and unfortunately a weak programme for government that does not talk about drug deaths. That is really disappointing.

I have a question about the diversionary threshold and the question the Vice Chair came to about being clear decriminalisation is of itself a good policy move, supported by both organisations. The caveat is that decriminalising substances, I think from the witnesses, was maybe not supported. If we follow that logic, if we decriminalise the person but not the substance, where is the diversionary threshold where it, in the witnesses' sense, potentially becomes somewhere where we have to refer someone to the police?

Comment on this
Dr. Bernard Kenny

We very much take the approach that, as we said before, addiction is a chronic relapsing condition, so we treat it like that. We would not be in favour of having a limited number of strikes where a person is caught in possession because if we look at the disease model of addiction, the very nature of it is people will have periods of recovery and unfortunately many people will relapse at times in their lives. Taking that on board, we would support in those situations that they would continue to be linked in with an appropriate healthcare provider, counselling service, talk therapy, psychotherapy or whatever is needed. That includes even residential care if warranted.

We would not support hard lines in that respect.

Comment on this

Regarding my second question, Dr. Crowley touched on a more holistic model around primary care. We spoke about some of the significant gaps. I think they came up again in respect of mental health provision. What does that look like in an ideal world?

Comment on this
Dr. Des Crowley

It is about increasing the skillset of the GP so that involves training. It involves resourcing the GP practice to have the time to do the work. The final bit is the referral pathway to other support services like talking therapies, psychosocial case workers and key workers dealing with all of the other aspects that are connected to the addiction. It is comprehensive, holistic and patient-centred.

Comment on this

In his piece, Dr. Kenny said that 350 GPs completed specialist training and the challenge relating to that. How much more additional resources are required in terms of that provision for GPs?

Comment on this
Dr. Bernard Kenny

A funding model is in place whereby GPs are resourced to provide the opioid agonist therapy programme. That is an agreement with the HSE that works very well. A total of 350 members are actively prescribing opioid agonist therapy. Part of our role in the college would be to see that expanded and that is what we would like. That is beneficial to the community. As part of that training, we do address other addictions so it is not purely opioid. Unfortunately, there is no equivalent programme from the HSE with regard to funding other substances so it relates purely to opioid agonist therapy. As I mentioned before, we recognise that addiction is a chronic disease in many cases with relapsing so it would be a suitable programme to expand into other substances like cocaine, cannabis use disorder, etc.

Comment on this

The witnesses from the Irish Pharmacy Union spoke about how they reached out to stakeholders, particularly those in Portugal. Could they tell us what they learned from the Portuguese. I think a lot of us would have concerns about some of it but from what I have seen, other bits have worked really well. What was the Portuguese experience? Regarding the comment that it came and went, that happened in Limerick in crack cocaine. It came and went but is now back with a bang so we should be careful - as I am sure, the witnesses are. I do not wish to say anything that would be misrepresented.

Comment on this
Ms Sinéad McCool

This is from a pharmacy perspective in that we met with our Portuguese pharmacist colleagues via the Pharmaceutical Group of the European Union, PGEU. Their experience was very positive. We spoke about things happening in parallel. The background was that Portugal had a serious issue with opioid misuse in the late 1990s so the government came together to form a body to put this in place with the five pillars. It happened very quickly. We said we were quite used to people having great ideas but they are very slow to happen. If memory serves me, they said the whole thing was up and running within a year to 18 months, so it was a real eye opener for us to see that it did happen. Their piece happened quite quickly within those 18 months, so they would have had the resources put in place be they needle exchange or opioid substitution programmes. It was the resourcing piece. Overall, it was a positive experience and they were very happy with it and they could see other improvements. It facilitated working within the community. The community education piece happened because there was access to these services. There was access to needle exchanges. As was talked about earlier, these were mothers, sons, daughters and families. From their perspective, it was very positive.

I will not use the word "complacency" but the one thing they said was that it was so good that they almost forgot how lucky they were to have it. Again, this is a pharmacy perspective. They did talk about how if issues arose, they were referred to commissions and took on undertakings so that no further actions were taken. They did not have a lot of experience of that but they did feel that they got referrals to services via those. Again, it fed back into decriminalising the patient and getting him or her the care and supports he or she needed. At a point, their opioid substitution programme stopped because it had been a success and there was no need for it. The needle exchanges continued because, again, they are an outreach service and a way of engaging somebody and, hopefully, starting him or her on the path to considering engaging with opioid substitution and trying to cease drug abuse. That was the perspective from our Portuguese colleagues.

Comment on this
Mr. Tom Murray

From a specific practitioner point of view, it involves the accessibility of pharmacists in terms of screening, recognising and sign posting and increased patient accessibility to addiction services as well as the increased use of needle exchange, opioid substitution therapy and harm reduction services, which could become available through an Irish pharmacy if properly resourced. The Portuguese certainly built on the model of accessibility of pharmacists in the communities for that. There are 78 million visits to pharmacies in a year, so we are ideally placed to take on that role if it is resourced, trained and put into place in the correct manner.

Comment on this

The law engagement and assisted recovery, Lear, project in Limerick, which is done with the Ana Liffey Drug Project. Gardaí can refer people to Ana Liffey as opposed to criminalising them straight off the bat and it is working really well. In the absence of legislation, we should be going down that road. HHC in cannabis is presenting anecdotally. What concerns do the witnesses from the Irish College of General Practitioners have about psychosis resulting from HHC in cannabis?

Comment on this
Dr. Bernard Kenny

We raised this issue earlier. HHC is the compound. It is similar to the issue that was dealt with a few years ago regarding head shop drugs.

Comment on this

When they criminalised head shops.

Comment on this
Dr. Bernard Kenny

It is a novel psychoactive substance derived from CBD, which is not psychoactive in itself. The law is playing catch up with that. We would have concerns because we see it as a harmful substance that is readily available to purchase.

Comment on this

I will stay on the issue of access to opioid substitution therapy. I know what the witnesses are saying, namely, that it is so much more complicated than that. Can we stick to the detail of that because I am interested in accessibility of opioid substitution therapy in an meaningful way? I fully admit that part of that is because I represent an area where there is a very strong concentration of services and I am aware that people travel to my area to get services when they are in addiction and need support. A total of 350 GPs are trained in level one or level two of opioid substitution therapy?

Comment on this
Dr. Bernard Kenny

A total of 350 GPs actively prescribe opioid substitution therapy. They are actively engaged in prescribing it.

Comment on this

Is that unrelated to level one and level two training?

Comment on this
Dr. Bernard Kenny

Level one and level two are different categories. Level one is the more fundamental training in addiction medicine.

Comment on this

It is basic. It is a case of "If you have had a crisis and have met with a specialist then I can be your everyday support".

Comment on this
Dr. Des Crowley

The big difference is that level two can initiate whereas level one can only take a patient who has already initiated treatment.

Comment on this

Of the 350, what is the breakdown? How many of those 350 are low-level and how many are people who can initiate?

Comment on this
Dr. Bernard Kenny

Roughly one third. The proportion has changed a bit.

Comment on this

One third would be level two?

Comment on this
Dr. Bernard Kenny

Yes.

Comment on this

Maths is not my strong point. If 350 represents about 8% of GPs, one third are people who initiate opioid substitution therapy.

Comment on this
Dr. Bernard Kenny

Probably in the eighties. That would be people based in GP community practices outside the HSE centres.

Comment on this

That means about 3% of GPs can initiate opioid substitution therapy.

Comment on this
Dr. Des Crowley

The majority of all opioid substitution therapy patients are initiated by GPs working in HSE services.

Comment on this

Are the witnesses aware of the regional layout of those services and access to them? Do they feel there is a good regional spread?

I am trying to get to the bottom of why I have seen people travel to us in Dublin 1 to access services. It is not just because we have those services. There must be a lack in their own areas because people do not want to travel unless they have to.

Comment on this
Dr. Des Crowley

There are regional problems with people accessing OST. Some of those problems are related to geography. If a person lives in a rural area it is hard to figure out how to provide care to them, although remote care might be one option. There are people waiting for OST treatment in the country.

Comment on this

Is there anything the Irish College of General Practitioners is working on to actively address that? Is there a level of discomfort for some GPs in dealing with this?

Comment on this
Dr. Bernard Kenny

Like everybody in the population, GPs have their own levels of comfort or discomfort and their own experiences. Some GPs trained in inner city areas and they are used to dealing with issues associated with social deprivation and addiction. For others, it is completely outside of their comfort zone. As part of our remit, we promote addiction medicine as a specialty. I refer to part of the broader approach to destigmatisation and depenalisation of people who suffer with addiction. Enforcing that for society as a whole will help to address that demand. It is an important issue and we recognise that ideally people should be treated by their GP, but it depends on that GP's training and level of expertise.

Comment on this

What happens if a person’s local GP, who they have dealt with all their life, says they will not do this?

Comment on this
Dr. Bernard Kenny

In the vast majority of cases, the GP will refer the person to the appropriate service.

Comment on this

What if the person lives in Naas and they are being referred to Dublin 1?

Comment on this
Dr. Des Crowley

There is a service in Naas, so you should-----

Comment on this

I picked a bad example. Can we pick another example?

Comment on this
Dr. Des Crowley

There is a service for every part of the country but does that mean if I am living in some part of Offaly that I may need to travel 40 miles to get to a service? The answer is "Yes".

Comment on this

When there is a GP down the road.

Comment on this
Dr. Des Crowley

Yes. That is the problem. There are people who cannot access their local community primary care service and they have to go to a specialist service which is a considerable distance from where they live. That has improved slightly because with Covid we were able to start providing remote care, which is very beneficial in that scenario. The advent of Healthmail, the IT system which allows us to send prescriptions directly to the pharmacy, definitely has improved things. However, there is capacity to look at those blackspots around the country and to ask what resources need to be put in, what the issue is and how can we eliminate the waiting list.

Comment on this

I am aware this is a question for the Department of Health to answer, but I hope there is a map that shows black holes in the provision.

Comment on this
Dr. Des Crowley

We do collect data on waiting times for OST. It is one of the national key performance indicators, KPIs.

Comment on this

I know I am out of time, but anecdotally I have been given the impression that there is a similar issue for some pharmacies, in that they do not want to stock certain OST-related products.

Comment on this
Mr. Tom Murray

As colleagues outlined, some pharmacists are comfortable with certain levels of professional practice while others may not have had the demand for the service and therefore do not have experience. I do not think that means they are objectively against it, but that they need that education, training and support to offer the service.

Comment on this

If they are objectively or unobjectively against it, where is the point of interaction with your organisation?

Comment on this
Mr. Tom Murray

We would be promoting a professional service that is patient-centred and patient care-centred. We would be providing the service of the training and supporting them through that so they could offer the service. We proactively promote that with members. I live in rural Donegal and the Deputy spoke about access to care. Sometimes it is not just whether the service exists in the county, but whether there is the infrastructure for people to get to that service.

Comment on this
Mr. Tom Murray

Whether there is a lack of public transport to get there or affordability of other forms of transport such as taxis, it is much easier for a person to turn around and get treatment from friends on the street than to access care that they are geographically prohibited from accessing.

Comment on this

It is a huge barrier in day-to-day life.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

We have to move on.

Comment on this

I may not have been clear earlier with regard to decriminalisation. I am not saying that you do not enter into something unless you have a spectacular, utterly perfect framework. If we wait for that, we will never do anything. I accept that everything we have done to date has not dealt with this situation. Mr. Murray, among others, spoke about the need to introduce that framework in parallel with other things. That makes complete sense. I also accept that at times in here there is an element of people talking out of both sides of their mouths. When talking about something novel or whatever, there can be this idea of going easy on people and where derogatory terms and the rest will be used. The problem I generally have with that commentary is that nothing radical is being proposed from a policing point of view or whatever. There is no one in this building who could say what it would take to out-police the drug problem. It is not something that people would countenance in any way, shape or form. I am very glad we are having this conversation but there is a wider conversation to be had. It has to be real.

I welcome, as Dr. Quinlan said, the piece around the whole-system basis. That is applicable across the board. Mr. Murray talked about community education and bringing people along to be sure we introduce the necessary services and get buy-in. We have a normalisation of kids seeing things they could not see 20 years ago, other than possibly in parts of Dublin and wherever else. I see how things have changed even in Dundalk over recent years and what is acceptable and what we accept ourselves from time to time. We do need to be able to deal with that. As we go down this road, it will create anomalies and unintended consequences that have to be dealt with.

As a follow on from what Deputy Quinlivan was talking about, a considerable number of kids are using vapes. Every second child is using one, or probably more. Many of them are probably putting more than bubblegum flavoured nicotine in them, such as THC and whatever else. We are seeing a significant number of issues in regard to it. I imagine the witnesses are seeing those numbers spiking at the moment. That obviously creates a lot of difficult circumstances in trying to manage those kids away from that. We are dealing with huge issues such as psychosis. Where do we go with that?

Comment on this
Dr. Bernard Kenny

Part of that question is related to-----

Comment on this

The number is related to this but people have come to me in the last while about the kids.

Comment on this
Dr. Bernard Kenny

We would not want anyone to be confused. We support decriminalisation of people who use drugs. As GPs we look after the person.

Comment on this

It is a separate question.

Comment on this
Dr. Bernard Kenny

Saying that, we do not condone or support drug use in any way. We recognise the harm of substances and that is why we are in the jobs we are in. We see the damage they do. We do not promote the use of substances-----

Comment on this

Has Dr. Kenny seen an increase in kids doing this in the last while?

Comment on this
Dr. Bernard Kenny

Personally, I work in the-----

Comment on this

I have seen it. I suppose it is about looking at a means of dealing with it.

Comment on this
Dr. Des Crowley

Through our adolescent services we have seen an increase in people presenting. The services have documented situations where people have had extreme psychotic episodes and required long-term treatment.

Comment on this

We are now dealing with far more intergenerational addiction and I know that anyone involved in youth services would say that where once a child could go to their grandmother, they cannot necessarily do that now. That is an awful thing to say. That means greater levels of supports are necessary to help people when they find themselves in these circumstances. We know that we do not have wraparound services, which I am sure is a situation our witnesses have come across in the last while, or is it?

Comment on this
Dr. Denis O'Driscoll

Yes, of course. There are scenarios where the addiction is cascaded down through the family unit.

Comment on this

Again, it is about the need for that framework. What we need now is a hell of a lot more complex than what we needed ten years ago and we obviously do not have it.

Comment on this
Dr. Des Crowley

The recognition of adverse events as part of the journey of addiction is very important. That is clearly documented. There is an onus on any system to try to stop that intergenerational addiction because experience of addiction is in itself an adverse childhood event for the child of the parent who is addicted. If we want to be serious about this-----

Comment on this

If we are serious about this, we are into early interventions in families and communities. We know what we need to do and that is breaking poverty and diverting people. In an awful lot of cases, youth diversion is worth doing, but in some cases it is too late.

In fairness, that is what Dr. Quinlan said about benzos. We can stop people going down particular roads while accepting that there is no magic bullet for any of this.

Comment on this
Mr. Tom Murray

Part of the education piece has to be around what is perceived to be socially acceptable drugs misuse and drugs abuse. There is a kind of snobbery whereby if you are using heroin, you are in one category, but if you are well-heeled, economically well-off and using cocaine at the weekend, then what is the harm? There is a whole educational piece around that in terms of recognition of where that drugs misuse and abuse is and around targeting services there as well rather than taking a tunnel vision view of what drugs misuse looks like.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

I wish to make three points. I might then give an opportunity for people to comment or deal with any unanswered questions that arose throughout the session before we wrap up.

On doctors, GPs or whomever being able to refuse care, reproductive rights is obviously one area in which that happens but that has been the subject of a constitutional debate for years when it comes to the religious context and all the different kinds of beliefs and stuff. When it comes to drug use and being able to refuse to become a prescriber, I understand that addiction exists across the spectrum but, as has been said, drug users put themselves in hierarchies. They always have adopted a view of "I am not as bad as them", "I do not do that" or "I do not use needles," but it feels as if there is a huge level of classism involved when doctors can say they are uncomfortable. If people train to a high professional level and complete extra specialist training - it is great to have such training - that is great, but what if someone has to deal with a person who has a rare disease and says that they are not comfortable taking them on as a patient because he or she is not a specialist? It seems that allowances are being made in respect of addiction and that people have to complete specialist training before they can become prescribers. What is the position culturally within the profession? I am not into shaming people because that does not solve anything, but is there a cultural push towards the view that such an attitude is not good enough from a professional?

Comment on this
Dr. Diarmuid Quinlan

I absolutely agree. GPs address a broad spectrum of illnesses. I treat people from cradle to grave. I provide palliative care, antenatal care and everything in between. Having said that, there are areas that I am better at and areas I am not as good at. Yesterday, I was in the Department of Health with the rare diseases group talking about how do we identify, manage and support people with rare diseases. Most GPs will deal with a very small number of people with rare diseases, and we depend on our specialist colleagues in that situation. For many GPs, the situation is very similar with addiction services. As part of our GP training we have an understanding of the matter. We are able to identify people and direct them to appropriate services. These patients require and deserve that specialist level of care. Therefore, it is appropriate for GPs to identify these people and signpost where they should go. We cannot prescribe for every condition. There are over 500 medical conditions. These are very specialist services and it is important that we have the training and skills to identify these people and refer them to appropriate colleagues in a timely, accessible and equitable fashion.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Is there an issue in the medical profession beyond GP-specific training in terms of the curriculum and being able to train to be a doctor and understand the social contexts in which they are going to work? Obviously, some social contexts are going to be different as a result of environmental factors, poverty and all of that. Doctors obviously have to choose to either become GPs or go into some other branch of medicine. Outside specialisation, should there not at least be some level of competency in order that people will be medically trained and understand people from all walks of life regardless?

Comment on this
Dr. Des Crowley

I totally agree. That comes down to understanding the social determinants of health-----

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Yes.

Comment on this
Dr. Des Crowley

-----and how important they are in terms of health outcomes.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Yes.

Comment on this
Dr. Des Crowley

That is for everybody, because people have no idea or realisation of how they impact individuals' lives or mortality and morbidity in communities.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Yes.

Comment on this
Dr. Des Crowley

It is devastating in terms of that life expectancy gap between people who live in affluent areas and those who live in disadvantaged areas.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Yes.

Comment on this
Dr. Des Crowley

Those are the social determinants. There could be more focus in our undergraduate and postgraduate training----

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Yes.

Comment on this
Dr. Des Crowley

-----in the context of understanding social determinants and how they can be managed.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Diversifying the profession should be a long-term goal. Doing so would bring in all of that different learning because there are different types of people working in medicine.

On novel benzos, we saw the recent reports about the Irish Prison Service and Portlaoise Prison. We have had novel benzos in the past, have we not? I do not know if the problem is recognised as that. A few years ago, across Bluebell and Inchicore, there were several deaths. People locally stated that this was caused by a bad batch of "Nike" tablets, which are street benzos. Are we saying that, potentially, each time a novel benzo comes up, it contains different components? Are enough testing and research being done on what is contained in each iteration of novel benzos?

Comment on this
Dr. Denis O'Driscoll

In my experience, you are never aware of what it is until you get hold of a sample in order to test. The issue with testing is that sometimes you are looking for a needle in a haystack. I say that with no disrespect to the testing process. There are so many varietals of the various forms of what is even contained in some of the street benzodiazepines. At one stage, etizolam was the most popular one. Then they had Flubromazolam in some others. Then they had tramadol mixed into others and a bit of paracetamol in others. It is very hard to determine exactly which one we are looking at. Much of our information comes from the European Drug Agency and from the Department of Health's early warning and emerging trends data that it gets from the Garda and Forensic Science Ireland. That is what we are seeing, and then we can determine what it may or may not be. Each benzodiazepine may or may not have higher effects, if that makes sense. Etizolam has more potency. I hate using that word when it comes to compounds. Etizolam has a more significant effect than benzodiazepines that are being prescribed. Hence, it was never made available for human use.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

I think it was in Canada - I apologise if I have the location wrong and I will double-check it for the record - where there was an initiative recently whereby drug dealers were encouraged to bring their supplies, especially if something had happened, to be checked and were provided with receipts. Those receipts were then shown to the people who wanted to buy the drugs. I know some people will panic the moment you mention drug dealers, but they are part of the supply chain. It is good thinking to include them in the conversation, particularly when something goes wrong. We are not there yet in Ireland, but what is the position with regard to amnesties within the community and people handing over drugs?

Comment on this
Dr. Denis O'Driscoll

The Welsh Emerging Drugs and Identification of Novel Substances, WEDINOS, project is probably one of the better examples near to us. People in Wales can send their sample of product to WEDINOS, which will test it and tell them what it contains. To give credit to the HSE, doing that at the festivals here is probably the first foray into that kind of area.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Yes.

Comment on this
Dr. Denis O'Driscoll

I see nothing wrong with that. It is only part of harm minimisation and harm reduction.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Yes.

Comment on this
Dr. Denis O'Driscoll

It is just another step towards having openness about it and an approach whereby it is a case of "If you want to use drugs, then I want you use drugs in the safest way possible to allow me to support you". It is about going down to that level. From my perspective, I see nothing wrong with that. How it would be managed is the question. Some locations that do drug testing worry about that whole piece where you have the drug dealer sending in the drug to be tested and then saying online that they have the best product available.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Regardless of people not wanting the whole trade of drug dealing, you definitely have to accept that drug dealers exist.

Comment on this
Dr. Denis O'Driscoll

Yes.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

If we can increase ethical standards, then I am all for it. Are there any unanswered questions before we wrap up? Does Dr. Crowley want to come in?

Comment on this
Dr. Des Crowley

I just want to make a point. We cannot forget about the link with HIV. I would like to underline the effectives of our OST services over 20 years in really eliminating HIV infection in people who use or inject drugs. There may be one or two very occasional new infections. However, in the area I have worked in, we have not had a new HIV infection in people who use drugs for maybe ten or 15 years. It is important to look at there being no obstacles to safe needle access and injecting equipment, because not alone is it about HIV, it is also about hepatitis C, which is a much more easily transmissible virus.

We are spending millions on our hepatitis C treatment programme, which is very effective. It is now in the community and GPs are involved. If people are continuing to inject, the risk of reinfection is enormous, we have to go back over it again and we also have resistance regarding the type of drugs that can be used. If we are looking at legislation, there should be no barriers. If somebody rocks up to their local pharmacy and need a needle exchange, it should be provided there. If they are in their OST clinic, they should be able to get it there. If they are going to a stand-alone needle exchange, that should be provided as well.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

On that point, I know you are not here from the HSE. I am not sure who can answer this. It is about paraphernalia such as crack pipes specifically. I am sure it is possible to transmit hepatitis C via such paraphernalia. Is procurement getting in the way of providing crack users with the pipes they are saying are the most comfortable for them? There were reports on the ground that in some of the services that were giving out crack pipes, there was a certain crack pipe that suited users, I am not sure of the reasons, they liked it, but then there was a complete change. Some of the users were saying the services had gone for a different supplier, but it is not the actual paraphernalia that is preferred.

Comment on this
Dr. Des Crowley

I am not aware. I just know that we are providing pipe paraphernalia in our needle exchanges on our side of the city. I have not heard that there has been a problem but I am not saying there is not. I do not know.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

Some of them in Tallaght were ending up switching back to other ones. I am told it is the same in Ballyfermot.

Comment on this
Dr. Diarmuid Quinlan

The citizens' assembly saying, "No decisions about us without us" could feed into what you are saying.

Comment on this

Is there a role for GPs and pharmacists on the drugs task forces? Do our guests have a view on that?

Comment on this
Dr. Denis O'Driscoll

I will revert back to my old HSE lands. I was a member of three different task forces by virtue of being a HSE employee, not as a pharmacist. I do think there is certainly a role for the local community providers. Essentially, the GPs and pharmacists in the local communities are probably doing the majority of the provision of services. It is a good idea for them to be on these task forces. I am not sure how that happens, as in how they could get into it time-wise.

Comment on this
Dr. Des Crowley

They need protected time in their contracts. We are front of house delivering services. To get time away from that would require a commitment that acknowledges it as important. It is vital that the people providing the services are sitting around the table when we discuss it in the bigger context the issues for communities.

Comment on this

The next module will deal with communities. Hopefully we will get there. We are trying to visualise what this would look like and where and how we could enhance services that are already being provided. It would be important to include such recommendations in any interim report.

Comment on this
Dr. Des Crowley

There is one other point. I do not want to hog the time. It is about the lived experience and being involved in the planning. It is important when decisions are being made. We talked about the development of services but you must have people around the table who have lived experience and can provide the nuance around access, where they feel stigma, where the blocks are and what they need in terms of recovery.

Comment on this
Lynn Ruane An Leas-Chathaoirleach Independent

I think that is it. I want to thank both the pharmacy union and the ICGP. That was a really good session in which we covered much that had not been covered previously. It went outside the realms of decriminalisation but the discussion was still underpinned by that being an important factor with all the other work that is being done. I thank all who contributed. I remind members that there is a private meeting on Tuesday. We will come back with a time for that.

Comment on this